The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have Unresectable non-small cell lung cancer (NSCLC). The purpose of this study is to find out if adding a study drug (MEDI4736 [durvalumab]) during chemotherapy and radiation therapy is better or worse than the usual approach for your advanced non-small cell lung cancer. The usual approach is defined as chemotherapy and radiation given together followed by the MEDI4736 (durvalumab) for one year.
If you join this study you will be randomly assigned to receive either MEDI4736 (durvalumab) during chemo/radiation or chemo/radiation alone for about 6 weeks followed by one additional year of MEDI4736 (durvalumab) alone. There is no standard chemotherapy regimen, and your treating physicians will select either cisplatin/etoposide, cisplatin/pemetrexed, or carboplatin/paclitaxel based upon their impression of which drugs are best for you. After the 1 year of study treatment or observation, your doctor will continue to follow your condition for 9 years. The total duration of the trial is 10 years.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04092283